These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1424044)

  • 1. Interventions that beneficially influence the evolution of coronary atherosclerosis. The case for calcium channel blockers.
    Waters D; Lespérance J
    Circulation; 1992 Dec; 86(6 Suppl):III111-6. PubMed ID: 1424044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium channel blockers and coronary atherosclerosis: from the rabbit to the real world.
    Waters D; Lespérance J
    Am Heart J; 1994 Dec; 128(6 Pt 2):1309-16. PubMed ID: 7977012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Modification of coronary arteriosclerosis in man by calcium antagonists?].
    Schneider W; Roebruck P; Cieslinski G; Noack H; Kober G; Alle M; Kaltenbach M
    Z Kardiol; 1991; 80 Suppl 9():63-71. PubMed ID: 1796651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Can the progression of coronary heart disease be modified by calcium antagonists?].
    Schneider W; Roebruck P; Kober G; Alle M; Cieslinski G; Mildenberger D; Satter P; Kaltenbach M
    Z Kardiol; 1989; 78 Suppl 5():112-20. PubMed ID: 2698562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Is regression of coronary sclerosis possible?].
    Krayenbühl HP
    Schweiz Rundsch Med Prax; 1993 Nov; 82(47):1348-53. PubMed ID: 8272700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of calcium antagonists in progression of arteriosclerosis. Evidence from animal experiments and clinical experience. Part II. Clinical experience with preventive effects of calcium channel blockers in atheromatous coronary artery disease.
    Just H; Frey M
    Basic Res Cardiol; 1994; 89 Suppl 1():177-84. PubMed ID: 7945172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium channel blockers and atherosclerosis.
    Henry PD
    J Cardiovasc Pharmacol; 1990; 16 Suppl 1():S12-5. PubMed ID: 1706008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of calcium antagonists and atherosclerosis.
    Keogh AM; Schroeder JS
    J Cardiovasc Pharmacol; 1990; 16 Suppl 6():S28-35. PubMed ID: 1707112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effect of two calcium channel blockers--nifedipine and diltiazem--on atherogenesis in hypercholesterolemic hamster.
    Raicu M; Pojoga L; Simionescu N; Simionescu M
    J Submicrosc Cytol Pathol; 1996 Apr; 28(2):265-75. PubMed ID: 8964051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concept of an antiatherosclerotic efficacy of calcium entry blockers. INTACT Investigators.
    Jost S; Rafflenbeul W; Deckers J; Wiese B; Hecker H; Nikutta P; Lippolt P; Lichtlen P
    Eur J Epidemiol; 1992 May; 8 Suppl 1():107-19. PubMed ID: 1505647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surrogate end-points: the case of trials on coronary atherosclerotic plaque regression.
    Marchioli R; Prieto JC; Tognoni G
    Clin Trials Metaanal; 1994 Oct; 29(2-3):139-76. PubMed ID: 10150224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydropyridine calcium antagonist modulates cholesterol metabolism and eicosanoid biosynthesis in vascular cells.
    Nicholson AC; Etingin OR; Pomerantz KB; Summers BD; Friday K; Wolff AA; Hajjar DP
    J Cell Biochem; 1992 Apr; 48(4):393-400. PubMed ID: 1315789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of calcium antagonists on atherosclerosis progression and intima media thickness].
    Zannad F
    Drugs; 2000; 59 Spec No 2():39-46. PubMed ID: 11002857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of calcium antagonists in the treatment of atherosclerosis and hypertension.
    Ouchi Y; Orimo H
    J Cardiovasc Pharmacol; 1990; 16 Suppl 2():S1-4. PubMed ID: 1369701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Calcium channel blockers and atherosclerosis].
    Hirata K; Yokoyama M
    Clin Calcium; 2004 Jan; 14(1):128-32. PubMed ID: 15576968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacologic prevention of cardiovascular diseases with calcium antagonists].
    Rafflenbeul W
    Z Kardiol; 1992; 81 Suppl 4():211-20. PubMed ID: 1290301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of the prospective randomized evaluation of the vascular effects of Norvasc (amlodipine) trial: PREVENT.
    Mancini GB
    Can J Cardiol; 2000 Jul; 16 Suppl D():5D-7D. PubMed ID: 10932029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic, antivasoconstrictor, and antiatherosclerotic effects of calcium antagonists in animal models of atherosclerosis.
    Hof RP; Tapparelli C; Weinstein DB
    J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S7-12. PubMed ID: 1695307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of coronary calcification in relation to age, gender and risk factor profile in the insight population.
    Motro M; Shemesh J
    Br J Clin Pract Suppl; 1997 Apr; 88():1-5. PubMed ID: 9519500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium, calcium antagonists and experimental atherosclerosis.
    Paoletti R; Corsini A; Soma MR; Bernini F
    Blood Press Suppl; 1996; 4():12-5. PubMed ID: 8973776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.